Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2 - CE-MARC 2
Contribution To Literature:
The CE-MARC 2 trial showed that CMR was superior to NICE guideline-directed care.
The goal of the trial was to evaluate three treatment strategies among patients with suspected coronary heart disease (CHD), including: 1) cardiac magnetic resonance (CMR)-guided care, 2) myocardial perfusion scintigraphy (MPS)-guided care, and 3) National Institute for Health and Care Excellence (NICE) guideline-directed care.
Patients with suspected CHD were randomized to CMR-guided care (n = 481) versus MPS-guided care (n = 481) versus NICE guideline-directed care (n = 240).
- Total number of enrollees: 1,202
- Duration of follow-up: 12 months
- Mean patient age: 56 years
- Percentage female: 47%
- Percentage diabetics: 13%
- Patients with suspected angina at least 30 years of age
- Pretest probability of CHD 10-90%
- Suitable for revascularization
- Nonangina chest pain
- Normal MPS or cardiac computed tomography within the previous 2 years
- Clinically unstable
- Previous myocardial infarction, coronary revascularization, or contraindication to any study noninvasive imaging test
The primary outcome, incidence of unnecessary invasive angiography, occurred in 7.5% of the CMR group vs. 7.1% of the MPS group vs. 28.8% of the NICE guideline-directed care group (CMR vs. NICE, p value < 0.001; CMR vs. MPS, p value = 0.32).
Secondary outcomes, major adverse cardiac events (MACE) at 12 months, occurred in 2.5% of the CMR group vs. 2.5% of the MPS group vs. 1.7% of the NICE guideline-directed care group (CMR vs. NICE, p value = NS; CMR vs. MPS, p value = NS).
Among patients with suspected CHD, CMR-guided care resulted in a lower frequency of unnecessary invasive angiography versus NICE guideline-directed care. Unnecessary angiography was similar between CMR- and MPS-guided care. MACE was similar between groups.
Greenwood JP, Ripley DP, Berry C, et al., on behalf of the CE-MARC 2 Investigators. Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial. JAMA 2016;Aug 29:[Epub ahead of print].
Presented by Dr. John Greenwood at the European Society of Cardiology Congress, Rome, Italy, August 29, 2016.
< Back to Listings